<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp412775" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9007608</article-id><article-id pub-id-type="pmcid-ver">PMC9007608.1</article-id><article-id pub-id-type="pmcaid">9007608</article-id><article-id pub-id-type="pmcaiid">9007608</article-id><article-id pub-id-type="pmid">35303757</article-id><article-id pub-id-type="doi">10.1002/psp4.12775</article-id><article-id pub-id-type="publisher-id">PSP412775</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical&#8208;driven balance of population average and variability</article-title><alt-title alt-title-type="right-running-head">Trapezoid bioequivalence</alt-title><alt-title alt-title-type="left-running-head">SOUFSAF et al.</alt-title></title-group><contrib-group><contrib id="psp412775-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Soufsaf</surname><given-names initials="S">Sara</given-names></name><xref rid="psp412775-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>sara.soufsaf@umontreal.ca</email><email>fahima.nekka@umontreal.ca</email></address></contrib><contrib id="psp412775-cr-0002" contrib-type="author"><name name-style="western"><surname>Nekka</surname><given-names initials="F">Fahima</given-names></name><xref rid="psp412775-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp412775-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="J">Jun</given-names></name><xref rid="psp412775-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jun.li.2@umontreal.ca</email></address></contrib></contrib-group><aff id="psp412775-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Universit&#233; de Montr&#233;al</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Qu&#233;bec</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Sara Soufsaf and Jun Li, Facult&#233; de Pharmacie, Universit&#233; de Montr&#233;al, C.P. 6128, Succ. Centre&#8208;ville, Montr&#233;al, H3C 3J7, Qu&#233;bec, Canada.<break/>
Emails: <email>sara.soufsaf@umontreal.ca</email> and <email>jun.li.2@umontreal.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2022</year></pub-date><volume>11</volume><issue seq="100">4</issue><issue-id pub-id-type="pmc-issue-id">405382</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v11.4</issue-id><fpage>482</fpage><lpage>493</lpage><history><date date-type="rev-recd"><day>03</day><month>2</month><year>2022</year></date><date date-type="received"><day>12</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>15</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-05-06 16:16:46.687"><day>06</day><month>05</month><year>2022</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-11-482.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-11-482.pdf"/><abstract id="psp412775-abs-0001"><title>Abstract</title><p>Among the current approaches for the analysis of bioequivalence, the average bioequivalence (ABE) is limited only to the mean bioavailability, whereas the population bioequivalence (PBE) criterion aggregates both mean and variance in a general comparison formula. However, a rational bioequivalence criterion capable of judging specific drug considerations is always still preferred. As an alternative approach, we introduce an aggregate criterion, namely, the trapezoid bioequivalence (TBE), which includes the consideration of both mean and variance of the bioavailability and adapted weighting of a drug's therapeutic properties. We first applied our method to specific simulated scenarios to compare the strengths and weaknesses of current bioequivalence approaches and demonstrate the improvements brought by TBE. As well, the impact of sample size and variability on ABE, PBE, and TBE are assessed using a population pharmacokinetic model of methylphenidate. Our results indicate that TBE inherits the advantages of both ABE and PBE while greatly reducing their inadequacies. Through simulations with population pharmacokinetic models of specific scenarios, we confirm that (1) TBE does not encounter the overly permissiveness issue of PBE, (2) TBE respects the hierarchy to ABE (TBE =&gt; ABE), and (3) TBE assesses bioequivalence with a restriction on <mml:math id="jats-math-1"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> without an increase to type 2 errors. The clinically inspired simulations demonstrate TBE&#8217;s superiority in a realistic context and its potential usefulness in practice. Moreover, the parameter choice in TBE may be adapted according to the specific context of a drug's pharmacological and pharmacodynamic properties.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Fonds de Recherche du Qu&#233;bec&#8211;Sant&#233;
</institution><institution-id institution-id-type="doi">10.13039/501100000156</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada
</institution><institution-id institution-id-type="doi">10.13039/501100000038</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="12"/><word-count count="7476"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.4 mode:remove_FC converted:13.04.2022</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="psp412775-cit-1001"><string-name name-style="western"><surname>Soufsaf</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nekka</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>. <article-title>Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical&#8208;driven balance of population average and variability</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>:<fpage>482</fpage>&#8208;<lpage>493</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.12775</pub-id><pub-id pub-id-type="pmcid">PMC9007608</pub-id><pub-id pub-id-type="pmid">35303757</pub-id></mixed-citation>
</p><fn-group id="psp412775-ntgp-0001"><fn fn-type="funding" id="psp412775-note-0001"><p>
<bold>Funding information</bold>
</p><p>Sara Soufsaf reports a research grant from Fonds de Recherche du Qu&#233;bec&#8211;Sant&#233;. Fahima Nekka and Jun Li report research grants from the Natural Sciences and Engineering Research Council of Canada</p></fn></fn-group></notes></front><body id="psp412775-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp412775-list-0001"><list-item><p>
<bold>WHAT</bold>
<bold>IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Average bioequivalence (ABE) and population bioequivalence (PBE) are the current statistical analyses of bioequivalence. ABE does not consider the variability of bioavailability. PBE is an aggregate criterion that considers variability but poses hierarchy problems with ABE.
<list list-type="simple" id="psp412775-list-0002"><list-item><p>
<bold>WHAT</bold>
<bold>QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>Can we propose an aggregate bioequivalence criterion that addresses the flaws of ABE and PBE without adding limitations of its own?
<list list-type="simple" id="psp412775-list-0003"><list-item><p>
<bold>WHAT</bold>
<bold>DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>We propose the trapezoid bioequivalence (TBE) as a criterion that considers the mean and variance of bioavailability with flexible and drug&#8208;specific weights. We show that TBE can effectively be applied to compare formulations and respect hierarchy with ABE.
<list list-type="simple" id="psp412775-list-0004"><list-item><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>TBE might be implemented in bioequivalence studies as a flexible approach when a drug's interindividual variability is a limiting factor in prescribability and switchability.</p></boxed-text>
</p><sec id="psp412775-sec-0002"><title>INTRODUCTION</title><p>When the patent of an innovative drug expires, a generic can be approved with an abbreviated new drug application, which states that the generic is bioequivalent to the brand name formulation in terms of efficacy and safety.<xref rid="psp412775-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Indeed, only the absorption process might differ, and it must be assessed through the bioavailability.<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> The bioavailability is measured by the rate and extent of drug absorption, represented by the maximum concentration (C<sub>max</sub>) and the area under the curve (AUC) of the plasma concentrations, respectively. Statistical analyses have been proposed to determine the therapeutical equivalence between the test and reference formulations.<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Among the aggregate approaches, the US Food and Drug Administration (FDA) proposes the following three levels of bioequivalence: average bioequivalence (ABE), population bioequivalence (PBE), and individual bioequivalence (IBE).<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Because IBE is less used, we focus our work on ABE and PBE.</p><p>ABE applies to the averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations (<mml:math id="jats-math-2"><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mspace width="0.15em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:math>, respectively). ABE states that the test may be a substitute for the reference formulation if the difference between <mml:math id="jats-math-3"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math> and <mml:math id="jats-math-4"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math> is within 20%. Because ABE is a simple comparison of averages, the declared bioequivalent event can be challenged by largely different variances of two formulations. Consequently, ABE has been questioned for its limited applicability.<xref rid="psp412775-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="psp412775-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="psp412775-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> To correct the situation, an additional consideration was proposed by Sheiner<xref rid="psp412775-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> and Hauck and Anderson,<xref rid="psp412775-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> for example. These authors pointed out that the variability in bioavailability evidently translates to a low precision in predicting the efficacy, which led to the introduction of the PBE criterion.<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="psp412775-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="psp412775-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="psp412775-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="psp412775-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="psp412775-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>PBE considers the drug variability by accounting for the distribution of bioavailability metrics. Compared with ABE, it aggregates the mean and variance (<mml:math id="jats-math-5"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> and <mml:math id="jats-math-6"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>) into a one&#8208;step comparison by simultaneously considering <mml:math id="jats-math-7"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> &#8211;<mml:math id="jats-math-8"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> and <mml:math id="jats-math-9"><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:math>.<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="psp412775-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> PBE finds its use when addressing the issue of drug prescribability, which is defined as the substitutability of a test drug to a reference drug for the treatment of na&#239;ve patients.<xref rid="psp412775-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>Nonetheless, PBE does not automatically imply ABE, which leads to overly permissive and contradictory results.<xref rid="psp412775-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp412775-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp412775-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="psp412775-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The non&#8208;espect of hierarchy is a fundamental issue when combining two elements into one criterion. In fact, if <mml:math id="jats-math-10"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is smaller than <mml:math id="jats-math-11"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>, a larger difference between <mml:math id="jats-math-12"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math> and <mml:math id="jats-math-13"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math> is accepted with PBE,<xref rid="psp412775-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp412775-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp412775-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> thus offsetting the benefit of adding the variance in the evaluation. Hence, a better criterion is needed for a fair trade&#8208;off between average and variance to respect the natural hierarchical property.<xref rid="psp412775-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp412775-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Indeed, several adaptations were proposed in the literature, with some questioning the idea that PBE gives equal importance to <italic toggle="yes">&#956;</italic> and <italic toggle="yes">&#963;</italic>
<sup>2</sup> in the assessment of bioequivalence.<xref rid="psp412775-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="psp412775-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="psp412775-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="psp412775-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="psp412775-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="psp412775-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> As a solution, Hauck et al.<xref rid="psp412775-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp412775-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and Midha<xref rid="psp412775-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp412775-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> proposed to add a weight to <italic toggle="yes">&#963;</italic>
<sup>2</sup> that can be modified to alter the acceptable threshold of bioequivalence.</p><p>The objective of our work is to propose a new bioequivalence criterion, named trapezoid bioequivalence (TBE), which simultaneously takes into account the average (<italic toggle="yes">&#956;</italic>) and variance (<italic toggle="yes">&#963;</italic>
<sup>2</sup>) of bioavailability by addressing the flaws of ABE and PBE without adding new limitations. Moreover, the goalpost of the new criterion for establishing bioequivalence should not become more permissive as the within&#8208;subject variability of the test drug is reduced, contrarily to PBE whose performance deteriorates in these cases. Finally, we add a trade&#8208;off between mean and variance that can be adjusted according to specific drug properties.</p><p>As a concrete drug example, we show how we can directly apply our proposed approach to methylphenidate (MPH), the main drug for attention deficit hyperactivity disorder. Because the interindividual variability (IIV) is very large for MPH, the dose individualization is especially difficult.<xref rid="psp412775-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="psp412775-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> By adopting TBE, we show how we can effectively establish bioequivalence between various formulations while reducing uncertainty related to substitutability. For an objective evaluation of bioequivalence, we have also used enriched clinical trial data for specific scenarios by incorporating population pharmacokinetic (pop&#8208;PK) modeling and simulation in our investigation.<xref rid="psp412775-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="psp412775-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p></sec><sec sec-type="methods" id="psp412775-sec-0003"><title>METHODS</title><p>The detailed ABE and PBE approaches are described in Supplementary Material S1.</p><sec id="psp412775-sec-0004"><title>Trapezoid bioequivalence</title><p>TBE is our proposed strategy to address the role of average and variance in bioequivalence evaluation, and most important the trade&#8208;off between both. Contrary to ABE or PBE, which use a single metric, TBE includes a trapezoid zone of acceptance outlined by two distinct sets of inequalities. This zone is expressed as:<disp-formula id="psp412775-disp-0001"><label>(1)</label><mml:math id="jats-math-14" display="block"><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mtext>zone</mml:mtext><mml:mtext>TBE</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:mfenced><mml:mfenced close="" open="|" separators=""><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>&#8208;</mml:mi><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8804;</mml:mo><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="0.277778em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.277778em"/><mml:mn>0</mml:mn><mml:mo>&#8804;</mml:mo><mml:mi>y</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup><mml:mi>&#894;</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>or</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8804;</mml:mo><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="0.277778em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.277778em"/><mml:mn>0</mml:mn><mml:mo>&#8804;</mml:mo><mml:mi>y</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>&#8208;</mml:mi><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>x</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mfenced></mml:mrow></mml:mfenced></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
</p><p>The explanation for each variable of TBE is given next, whereas the specific values chosen for these variables are detailed in the Scenario&#8208;Based Simulations methods section.</p><p>For the purpose of bioequivalence, we specifically define <mml:math id="jats-math-15"><mml:mrow><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> and <mml:math id="jats-math-16"><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math>. <mml:math id="jats-math-17"><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup></mml:math> is the maximal squared difference of <italic toggle="yes">&#956;</italic> allowed for bioequivalence; <mml:math id="jats-math-18"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> is the therapeutically acceptable difference of <mml:math id="jats-math-19"><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math> where TBE can be judged solely based on the difference in <italic toggle="yes">&#956;</italic>, and <mml:math id="jats-math-20"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> is the therapeutically unacceptable difference of <mml:math id="jats-math-21"><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math> beyond which TBE will directly fail. <mml:math id="jats-math-22"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> and <mml:math id="jats-math-23"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> are used to control the trade&#8208;off between <italic toggle="yes">&#956;</italic> and <italic toggle="yes">&#963;</italic>
<sup>2</sup>. Given these parameters, <mml:math id="jats-math-24"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> and <mml:math id="jats-math-25"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> are weights which regulate the trade&#8208;off between mean and variance and are computed as follows:<disp-formula id="psp412775-disp-0002"><label>(2)</label><mml:math id="jats-math-26" display="block"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp412775-disp-0003"><label>(3)</label><mml:math id="jats-math-27" display="block"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula>
</p><p>Specific values for <mml:math id="jats-math-28"><mml:mrow><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math> are to be defined by regulatory agencies according to the drug's pharmacological properties and its tolerance for IIV. In this work, we assigned values that would respect general clinical significance and would allow an agreement with ABE and PBE. Each of these values is explained in the Scenario&#8208;Based Simulations section in the Methods.</p><p>To facilitate the hypothesis test, Equation&#160;(<xref rid="psp412775-disp-0001" ref-type="disp-formula">1</xref>) can be transformed as:
<list list-type="bullet" id="psp412775-list-0005"><list-item><p>
<mml:math id="jats-math-29"><mml:mrow><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>&#8208;</mml:mo><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, when <mml:math id="jats-math-30"><mml:mrow><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8804;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math>
</p></list-item><list-item><p>
<mml:math id="jats-math-31"><mml:mrow><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfenced><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, when <mml:math id="jats-math-32"><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8804;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math>
</p></list-item></list>
</p><p>TBE can be dynamically accessed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mphss.shinyapps.io/SoufsafTrapezoidBE/" ext-link-type="uri">https://mphss.shinyapps.io/SoufsafTrapezoidBE/</ext-link>.</p><p>TBE conclusions are drawn based on the upper 90% confidence interval (CI) of the previous inequalities. The bootstrap procedure was used to compute the CI, and 2000 replicates were used for the bootstrap.<xref rid="psp412775-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> As in PBE, TBE is declared if this value falls below 0. Otherwise, TBE will not be concluded. The TBE acceptance zone (zone<sub>TBE</sub>) is illustrated in Figure&#160;<xref rid="psp412775-fig-0001" ref-type="fig">1</xref>a, and a flowchart of TBE computation and decision is presented in Figure&#160;<xref rid="psp412775-fig-0001" ref-type="fig">1</xref>b.</p><fig position="float" fig-type="FIGURE" id="psp412775-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>(a) Zones of acceptance of bioequivalence for average bioequivalence (ABE), population bioequivalence (PBE), and trapezoid bioequivalence (TBE) as shaded areas. <italic toggle="yes">&#956;<sub>T</sub>
</italic> and <italic toggle="yes">&#956;<sub>R</sub>
</italic> are the averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; <mml:math id="jats-math-33"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mspace width="0.15em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.15em"/><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> are the variances of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; <mml:math id="jats-math-34"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">TBE</mml:mi></mml:msup></mml:math> is the maximal squared difference of <italic toggle="yes">&#956;</italic> allowed for bioequivalence; <mml:math id="jats-math-35"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> is the therapeutically acceptable difference of <mml:math id="jats-math-36"><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math>; <mml:math id="jats-math-37"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> is the therapeutically unacceptable difference of <mml:math id="jats-math-38"><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math>; <mml:math id="jats-math-39"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> and <mml:math id="jats-math-40"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> are weights applied to control the trade&#8208;off between <italic toggle="yes">&#956;</italic> and <italic toggle="yes">&#963;</italic>
<sup>2</sup>. (b) Flowchart of bioequivalence decisions with TBE</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-11-482-g002.jpg"/></fig><p>Similar to PBE and in accordance with Equation&#160;(<xref rid="psp412775-disp-0001" ref-type="disp-formula">1</xref>), zone<sub>TBE</sub> is defined by limits in terms of <mml:math id="jats-math-41"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> and <mml:math id="jats-math-42"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>. When <mml:math id="jats-math-43"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, zone<sub>TBE</sub> corrects the drawback of ABE and adds a consideration of variability to bioequivalence. As well, when <mml:math id="jats-math-44"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, zone<sub>TBE</sub> corrects the drawback of PBE and imposes a limit to <mml:math id="jats-math-45"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math>.</p><p>As defined in Equation&#160;(<xref rid="psp412775-disp-0001" ref-type="disp-formula">1</xref>), TBE possesses multiple favorable properties. First, its limits are defined with a clinical significance for each parameter (<mml:math id="jats-math-46"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup></mml:math> and <mml:math id="jats-math-47"><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math>). Indeed, <mml:math id="jats-math-48"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup></mml:math> may be set in accordance with current ABE criteria, and <mml:math id="jats-math-49"><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math> may be set in accordance with clinically acceptable limits of variability. Second, it can be shown that TBE is reduced to ABE assuming <mml:math id="jats-math-50"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> and fixing <mml:math id="jats-math-51"><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup></mml:math> = <mml:math id="jats-math-52"><mml:mrow><mml:msup><mml:mi>ln</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mn>1.25</mml:mn></mml:mfenced></mml:mrow></mml:math>. Third, TBE respects the hierarchy with ABE. Indeed, TBE introduces <mml:math id="jats-math-53"><mml:msup><mml:mi>&#952;</mml:mi><mml:mtext>TBE</mml:mtext></mml:msup></mml:math> to prevent widening the acceptable limits of <mml:math id="jats-math-54"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> when <mml:math id="jats-math-55"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is reduced with respect to <mml:math id="jats-math-56"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>. Finally, TBE allows a flexible trade&#8208;off between mean and variance with the weights <mml:math id="jats-math-57"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> and <mml:math id="jats-math-58"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math>. Indeed, TBE permits a control on the weight and importance given to <mml:math id="jats-math-59"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> and <mml:math id="jats-math-60"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>. These favorable properties are examined in this work.</p><p>ABE, PBE and TBE were applied in three ways. First, we computed statistical methods of bioequivalence to broad scenario&#8208;based simulations applicable to all drugs. Second, we used MPH as a specific drug to exemplify our work. Third, we computed the type 1 and 2 errors.</p></sec><sec id="psp412775-sec-0005"><title>Scenario&#8208;based simulations</title><p>The scenarios chosen for simulation are combinations of the following situations: a relatively small variability for the test formulation (<mml:math id="jats-math-61"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn><mml:mi>T</mml:mi></mml:msubsup><mml:mi>&#8208;</mml:mi><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn><mml:mi>R</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:math>), a large mean difference between the test and reference formulations <mml:math id="jats-math-62"><mml:msup><mml:mrow><mml:mfenced close=")" open="(" separators=""><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#956;</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:msub><mml:mi>&#8208;</mml:mi><mml:msub><mml:mi mathvariant="normal">&#956;</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>&gt;</mml:mo><mml:msup><mml:mi mathvariant="normal">&#952;</mml:mi><mml:mrow><mml:mi>TBE</mml:mi></mml:mrow></mml:msup></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math>, a therapeutically tolerable difference of variability (<mml:math id="jats-math-63"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8804;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>&#8208;</mml:mi><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math>), and nonsubstitutable test and reference formulations (<mml:math id="jats-math-64"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>&#8208;</mml:mi><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math>). The first and second situations identify failures of PBE, whereas the third and fourth situations identify failures of ABE.</p><p>For each patient, the bioavailability metric values (AUC or C<sub>max</sub>) of test (or reference) formulations are drawn from normal distributions with means <mml:math id="jats-math-65"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mtext>or</mml:mtext><mml:mspace width="0.0606060606060606em"/><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:math> and variances <mml:math id="jats-math-66"><mml:msubsup><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mi mathvariant="bold">T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>
<mml:math id="jats-math-67"><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mtext>or</mml:mtext><mml:mspace width="0.166667em"/><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfenced></mml:math>. The fixed values of <mml:math id="jats-math-68"><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.166667em"/><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.166667em"/><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn><mml:mi>R</mml:mi></mml:msubsup></mml:math>, and <mml:math id="jats-math-69"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> are reported in Table&#160;<xref rid="psp412775-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="psp412775-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Results for the scenario&#8208;based simulations</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Scenario</th><th align="left" rowspan="2" valign="bottom" colspan="1">
<mml:math id="jats-math-70"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math>
</th><th rowspan="2" valign="bottom" colspan="1">
<mml:math id="jats-math-71"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>
</th><th align="left" rowspan="2" valign="bottom" colspan="1">
<mml:math id="jats-math-72"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">ABE</th><th colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">PBE</th><th colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">TBE</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">90% CI</th><th valign="bottom" rowspan="1" colspan="1">Probability of passing bioequivalence (%)</th><th valign="bottom" rowspan="1" colspan="1">Mean upper 90% CI (CV %)</th><th valign="bottom" rowspan="1" colspan="1">Probability of passing bioequivalence (%)</th><th valign="bottom" rowspan="1" colspan="1">Mean upper 90% CI (CV %)</th><th valign="bottom" rowspan="1" colspan="1">Probability of passing bioequivalence (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.0111</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">0.9529&#8211;1.2977</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="(" rowspan="1" colspan="1">0.4070 (12.86)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.0271 (&#8722;18.67)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0.0900</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">1.1572&#8211;1.5751</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.5069 (9.86)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.1317 (29.40)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">0.9174&#8211;1.4834</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">1.1530 (11.68)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.0953 (11.34)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0.0900</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.01</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">1.2894&#8211;1.4217</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.1918 (12.17)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.1347 (22.30)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0.0111</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.01</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">
<bold>1.0574&#8211;1.1651</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="char" char="(" rowspan="1" colspan="1">0.0142 (74.343)</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.0278 (&#8722;17.69)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">0.0111</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.1225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">0.9188&#8211;1.3461</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.3605 (15.42)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.0270 (&#8722;18.803)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">0.0900</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.1225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">1.1146&#8211;1.6374</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.4330 (15.28)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.1327 (33.158)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">0.0225</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="char" char="." rowspan="1" colspan="1">0.1225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">0.8885&#8211;1.5235</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">1.1009 (14.67)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">0.0948 (15.63)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">0.0900</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.1</td><td align="char" char="." rowspan="1" colspan="1">0.1225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">1.2287&#8211;1.5012</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.0476 (&#8722;80.4)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>85</bold>
</td><td align="char" char="(" rowspan="1" colspan="1">0.1388 (26.29)</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">0.0111</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.1</td><td align="char" char="." rowspan="1" colspan="1">0.1225</td><td align="char" char="&#x2013;" rowspan="1" colspan="1">
<bold>1.0059&#8211;1.2293</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>86</bold>
</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.1827 (&#8722;12.45)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="char" char="(" rowspan="1" colspan="1">
<bold>&#8722;0.0271 (&#8722;18.67)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>100</bold>
</td></tr></tbody></table><table-wrap-foot id="psp412775-ntgp-0002"><title>Note</title><fn id="psp412775-note-0002"><p>Values in bold signify that the approach passes bioequivalence. 90% CI indicates mean 90% CI across all replications.</p></fn><fn id="psp412775-note-0003"><p>Abbreviations: <italic toggle="yes">&#956;<sub>T</sub>
</italic> and <italic toggle="yes">&#956;<sub>R</sub>
</italic>, averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; <mml:math id="jats-math-73"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mtext>and</mml:mtext><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>, variances of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; ABE, average bioequivalence; CI, confidence interval; CV, coefficient of variation across all replications; PBE, population bioequivalence; TBE, trapezoid bioequivalence.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>For each scenario, 40&#160;subjects are used. Thus, 80 AUC measurements (two per subject) are simulated for a crossover and nonreplicated clinical trial. ABE, PBE, and TBE results are then computed for each scenario as described in the previous section. For the sake of respecting the desirable properties of bioequivalence criterion, we fixed TBE parameters in accordance with ABE&#8217;s and PBE&#8217;s FDA goalposts.</p><p>
<mml:math id="jats-math-74"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup></mml:math>: by fixing <mml:math id="jats-math-75"><mml:mrow><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mi>ln</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mn>1.25</mml:mn></mml:mfenced></mml:mrow></mml:math>, we respect ABE&#8217;s acceptable &#177;20% mean difference on the log scale (or 80%&#8211;125% on the original scale).</p><p>
<mml:math id="jats-math-76"><mml:msub><mml:mi mathvariant="bold-italic">&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math>: we fix &#177;30% as the tolerable difference of <italic toggle="yes">&#963;</italic>2 on the log scale as suggested.<xref rid="psp412775-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Clinically, this is a range of variance between 70%&#8211;143% on the original scale.</p><p>Using Equations&#160;(<xref rid="psp412775-disp-0002" ref-type="disp-formula">2</xref>) and (<xref rid="psp412775-disp-0003" ref-type="disp-formula">3</xref>), we have <mml:math id="jats-math-77"><mml:msub><mml:mi mathvariant="bold-italic">&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> = 0.1480 and <mml:math id="jats-math-78"><mml:msub><mml:mi mathvariant="bold-italic">&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> = 0.1026.</p><p>We repeated each sampling scenario&#160;100 times.</p></sec><sec id="psp412775-sec-0006"><title>MPH model&#8208;based simulations</title><p>In addition to the scenario&#8208;based simulations, we applied the described bioequivalence methods to the specific context of MPH. Indeed, as a drug with a higher IIV, it exemplifies the added value of using TBE instead of ABE or PBE.</p><p>The bioequivalence methods were applied to two types of data. First, it was applied to the analysis of a randomized clinical trial (Supplementary Material S2). Second, as the available clinical trial data were limited, we used model&#8208;based simulations to explore additional considerations pertinent to bioequivalence: IIV and sample size.</p><sec id="psp412775-sec-0007"><title>Interindividual variability</title><p>To explore the impact of IIV on the bioequivalence methods, we used the published MPH pop&#8208;PK model to simulate databases that incorporate interindividual and intraindividual variability.<xref rid="psp412775-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Each simulated pair of test and reference formulations is chosen with a random variance of IIV (<italic toggle="yes">&#969;</italic>2) listed in Table&#160;<xref rid="psp412775-tbl-0002" ref-type="table">2</xref> while the fixed effects and residual variability remained unchanged. Consequently, the <mml:math id="jats-math-79"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> and <mml:math id="jats-math-80"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> evaluated by PBE and TBE still depend on interindividual and intraindividual variability. However, as total IIV is the only difference between the reference and test databases, only the impact of IIV on ABE, PBE, and TBE is evaluated. The magnitude of IIV on each parameter was chosen according to a reasonable scale observed in pop&#8208;PK models. In staying true to the original pop&#8208;PK model, we did not explore any IIV on lag and fixed it for all simulations.</p><table-wrap position="float" id="psp412775-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Results for MPH model&#8208;based simulations</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Number of patients in clinical study</th><th align="left" rowspan="2" valign="bottom" colspan="1">Sum of IIV<xref rid="psp412775-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref> for the reference formulation</th><th align="left" rowspan="2" valign="bottom" colspan="1">Sum of IIV<xref rid="psp412775-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref> for the test formulation</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Results of bioequivalence</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">ABE</th><th align="left" valign="bottom" rowspan="1" colspan="1">PBE</th><th align="left" valign="bottom" rowspan="1" colspan="1">TBE</th></tr></thead><tbody><tr><td align="left" rowspan="10" colspan="1">40</td><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> = IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> &gt; IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">NO</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NO</italic>
</td><td align="left" rowspan="1" colspan="1">NO</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> &lt; IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NO</italic>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="10" colspan="1">100</td><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> = IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> &gt; IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">NO</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">YES</italic>
</bold>
</td><td align="left" rowspan="1" colspan="1">NO</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">IIV<sub>T</sub> &lt; IIV<sub>R</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">YES</italic>
</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>YES</bold>
</td></tr></tbody></table><table-wrap-foot id="psp412775-ntgp-0003"><title>Note</title><fn id="psp412775-note-0004"><p>Bold signifies that the approach passes bioequivalence. Italics and underline signify a result that changes according to the number of patients in the clinical study.</p></fn><fn id="psp412775-note-0005"><p>Abbreviations: ABE, average bioequivalence; IIV<sub>T</sub> and IIV<sub>R</sub>, interindividual variability for the test and reference formulations, respectively; MPH, methylphenidate; PBE, population bioequivalence; TBE, trapezoid bioequivalence.</p></fn><fn id="psp412775-note-0006"><label>
<sup>a</sup>
</label><p>IIV expressed as the sum of variance (<italic toggle="yes">&#969;</italic>
<sup>2</sup>) on ka<sub>1</sub> (first absorption constant); ka<sub>2</sub> (first absorption constant); F<sub>1</sub> (immediate release fraction of MPH), where <italic toggle="yes">&#969;</italic>
<sup>2</sup> is the variance of the normally distributed IIV <italic toggle="yes">&#951;</italic> ~ N(0, <italic toggle="yes">&#969;</italic>
<sup>2</sup>) and <mml:math id="jats-math-81"><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mtext>kal</mml:mtext><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8712;</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0.05</mml:mn><mml:mo>,</mml:mo><mml:mn>0.15</mml:mn><mml:mo>,</mml:mo><mml:mn>0.35</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math>; <mml:math id="jats-math-82"><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:mrow><mml:mtext>ka</mml:mtext><mml:mn>2</mml:mn></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8712;</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0.05</mml:mn><mml:mo>,</mml:mo><mml:mn>0.15</mml:mn><mml:mo>,</mml:mo><mml:mn>0.35</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mfenced><mml:mspace width="-1.2pt"/><mml:mo>&#894;</mml:mo><mml:mspace width="0.277778em"/><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8712;</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0.001</mml:mn><mml:mo>,</mml:mo><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mfenced><mml:mspace width="-1.2pt"/><mml:mo>&#894;</mml:mo><mml:mspace width="0.277778em"/><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mtext>lag</mml:mtext><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math>.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="psp412775-sec-0008"><title>Sample size</title><p>Subsequently, we explored the impact of sample size on ABE, PBE, and TBE. The same methods as noted previously were applied with 40 and 100&#160;subjects in each simulation. These numbers were chosen to investigate a realistic range observed in clinical trials.</p><p>TBE parameters used in the MPH model&#8208;based simulations were chosen exactly as in the Scenario&#8208;Based Simulations section in the Methods.</p></sec></sec><sec id="psp412775-sec-0009"><title>Type 1 and type 2 errors</title><p>The type 1 and type 2 errors of ABE, PBE, and TBE were evaluated through simulations of 1000 trials with a crossover and nonreplicated design. To evaluate the impact of sample size, the type 1 and type 2 errors were computed separately with sample sizes of 10, 20, 40, 60, 80, and 100.</p><p>First, we computed the type 1 error for simulated trials that follow the null hypothesis of bioinequivalence. Specifically, we chose to simulate pharmacokinetic measures from distributions where <mml:math id="jats-math-83"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.0498</mml:mn></mml:mrow></mml:math>. In keeping with the scenario&#8208;based simulations and the range observed in bioequivalence studies in Nakai et al.,<xref rid="psp412775-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> the value of <mml:math id="jats-math-84"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> was fixed to 0.0225. The type 1 error was computed as the proportion of the simulated trials that reject the bioinequivalence.</p><p>Second, we computed the type 2 error for simulated trials that follow the alternative hypothesis of bioequivalence where <mml:math id="jats-math-85"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, <mml:math id="jats-math-86"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>.0225. The type 2 error was computed as the proportion of the simulated trials that accept the bioinequivalence. In addition, we computed power curves by simulating trials with varying levels of <mml:math id="jats-math-87"><mml:mrow><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>&#8712;</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.01</mml:mn><mml:mo>,</mml:mo><mml:mn>0.04</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0498</mml:mn><mml:mo>,</mml:mo><mml:mn>0.09</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math> with <mml:math id="jats-math-88"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math>.</p></sec></sec><sec sec-type="results" id="psp412775-sec-0010"><title>RESULTS</title><sec id="psp412775-sec-0011"><title>Scenario&#8208;based simulations</title><p>For the three bioequivalence methods, five specific scenarios are chosen and tested as reported in Table&#160;<xref rid="psp412775-tbl-0001" ref-type="table">1</xref>. Each scenario is applied to a small variability <mml:math id="jats-math-89"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">R</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math> and a large variability <mml:math id="jats-math-90"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">R</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1225</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math>. Thus, we have 10 scenarios. To have more reliable conclusions, all scenarios were repeated 100 times. The results are also illustrated in Figure&#160;<xref rid="psp412775-fig-0002" ref-type="fig">2</xref>.</p><fig position="float" fig-type="FIGURE" id="psp412775-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>The conclusion of bioequivalence for average bioequivalence (ABE), population bioequivalence (PBE), and trapezoid bioequivalence (TBE) are represented as a scatter, and the bioequivalence zones are illustrated as shaded areas. Each cluster is identified with a text box referring to the scenario number in Table&#160;<xref rid="psp412775-tbl-0001" ref-type="table">1</xref>. <italic toggle="yes">&#956;<sub>T</sub>
</italic> and <italic toggle="yes">&#956;<sub>R</sub>
</italic> are the averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; <mml:math id="jats-math-91"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mspace width="0.15em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.15em"/><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> are the variances of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively. &#8730;, the approach passes bioequivalence; X, the approach fails to demonstrate bioequivalence. Top, scenarios for <mml:math id="jats-math-92"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math>; bottom, scenarios for <mml:math id="jats-math-93"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1225</mml:mn></mml:mrow></mml:math>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-11-482-g001.jpg"/></fig><p>In Table&#160;<xref rid="psp412775-tbl-0001" ref-type="table">1</xref>, the results of ABE, PBE, and TBE are presented pertaining to the CI and the percentage of all replications that conclude bioequivalence. Specifically, we report the average 90% CI across all replications for ABE analysis, and the average upper limit of the linearized 90% CI across all replications for PBE and TBE analyses. As well, to account for the results of each replication, we report the probability of passing bioequivalence as the percentage of all replications that conclude bioequivalence.</p><p>The results are summarized as follows, and the details are displayed in Figure&#160;<xref rid="psp412775-fig-0002" ref-type="fig">2</xref>:
<list list-type="bullet" id="psp412775-list-0006"><list-item><p>As expected, the scenarios where the clinically acceptable limits of <mml:math id="jats-math-94"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> and <mml:math id="jats-math-95"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> are exceeded never conclude bioequivalence (Scenarios 2 and 7).</p></list-item><list-item><p>The scenarios where solely the acceptable limits of <mml:math id="jats-math-96"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> are exceeded show cases where ABE has been criticized (Scenarios 3 and 8). Indeed, ABE only considers the mean <italic toggle="yes">&#181;</italic> and does not take into account the variability <mml:math id="jats-math-97"><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math>. By implementing <mml:math id="jats-math-98"><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math> in Equation&#160;(<xref rid="psp412775-disp-0001" ref-type="disp-formula">1</xref>), TBE corrects these situations. However, although these scenarios are found in zone<sub>ABE</sub>, the probability of concluding bioequivalence with ABE is null. This contradiction stems from its 90% CI&#8217;s sensitivity to sample size (Equation S2). When the sample size is large enough, 90% CI tightens and ABE can conclude bioequivalence. A larger sample size and the results are discussed further in the next section.</p></list-item><list-item><p>A scenario where the limits of ABE, PBE, and TBE are all respected concludes to bioequivalence for all methods (Scenario 10) with <mml:math id="jats-math-99"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1225</mml:mn></mml:mrow></mml:math>. With <mml:math id="jats-math-100"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math>, we can identify the first drawback of PBE. Indeed, due to its reference&#8208;scaled Equation (S4), PBE&#8217;s permissiveness depends on <mml:math id="jats-math-101"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>.<xref rid="psp412775-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Thus, the criterion PBE is expected to be stricter when <mml:math id="jats-math-102"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is decreased. In fact, PBE&#8217;s probability of concluding bioequivalence drops from 100% to 6% (Scenario 10 vs. 5). TBE corrects this drawback as its probability of concluding bioequivalence remains at 100% for either scenario.</p></list-item><list-item><p>For scenarios where the clinically acceptable limits of <mml:math id="jats-math-103"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> and <mml:math id="jats-math-104"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> are respected (Scenarios 1 and 6), we highlight cases where TBE accepts bioequivalence while ABE and PBE do not. Indeed, these scenarios do not fall inside zone<sub>PBE</sub>, and the null probability of passing bioequivalence with PBE is expected. In addition, similar to Scenarios 3 and 8, ABE does not pass bioequivalence due to a small sample size. Nonetheless, TBE still successfully concludes bioequivalence.</p></list-item><list-item><p>For scenarios where solely the acceptable limits of <mml:math id="jats-math-105"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> are exceeded, we show the second drawback of PBE. In fact, these are cases where PBE has been criticized and deemed too permissive compared with ABE.<xref rid="psp412775-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp412775-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp412775-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> It is clearly shown that, with <mml:math id="jats-math-106"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1225</mml:mn></mml:mrow></mml:math> and <mml:math id="jats-math-107"><mml:mrow><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>&gt;</mml:mo><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">ABE</mml:mi></mml:msup></mml:mrow></mml:math> (Scenario 9), PBE is the only approach that concludes bioequivalence. Conversely, if <mml:math id="jats-math-108"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is reduced to <mml:math id="jats-math-109"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math> (Scenario 4), PBE no longer concludes bioequivalence. TBE corrects this contradiction through <mml:math id="jats-math-110"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup></mml:math> and its probability of concluding bioequivalence is the same as ABE&#8217;s regardless of <mml:math id="jats-math-111"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>.</p></list-item></list>
</p></sec><sec id="psp412775-sec-0012"><title>MPH model&#8208;based simulations</title><p>To complement the results obtained from the clinical trial data (Supplementary Material S2), we used the model&#8208;based simulations to examine various levels of IIV, which were not observed in the MPH clinical trial data. The IIV was modified for three pharmacokinetic parameters: the first and second absorption (ka<sub>1</sub> and ka<sub>2</sub>, respectively) and the release of the external MPH fraction (F<sub>1</sub>).</p><p>Because the typical values for all parameters did not change, the mean pharmacokinetic profile was the same for all MPH model&#8208;based simulations. Thus, this section demonstrates differences between ABE, PBE, and TBE solely when the IIV is involved. Two sample sizes were tested to represent realistic numbers of patients enrolled in the MPH clinical trial and general bioequivalence studies.<xref rid="psp412775-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>The total IIV for ka<sub>1</sub>, ka<sub>2</sub>, and F<sub>1</sub> and the bioequivalence results for ABE, PBE, and TBE are presented in Table&#160;<xref rid="psp412775-tbl-0002" ref-type="table">2</xref>. As expected, ABE, PBE, and TBE always conclude to bioequivalence when the IIV is unchanged between the test and reference formulations (IIV<sub>T</sub> = IIV<sub>R</sub>) regardless of sample size.</p><p>When IIV<sub>T</sub> &gt; IIV<sub>R</sub>, PBE does not conclude bioequivalence in either of the two examples given in Table&#160;<xref rid="psp412775-tbl-0002" ref-type="table">2</xref> (IIV<sub>T</sub> = 1; IIV<sub>R</sub> = 1.5). In fact, this situation precisely represents the restrictiveness of PBE and its lack of drug&#8208;specific flexibility. On the other hand, ABE passes bioequivalence only if IIV<sub>T</sub> = 1, which can be explained with ABE&#8217;s sensitivity to sample size (this property is mentioned in the Scenario&#8208;Based Simulations section in the Results). In fact, when the sample size is increased to 100 and IIV<sub>T</sub> = 1, ABE passes bioequivalence. By contrast, TBE concludes to bioequivalence for both examples and both sample sizes because the IIV values respect the chosen TBE parameter used for MPH: <mml:math id="jats-math-112"><mml:mrow><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mi>ln</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mn>1.25</mml:mn></mml:mfenced><mml:mo>,</mml:mo><mml:mspace width="0.277778em"/><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mn>1.4286</mml:mn></mml:mrow></mml:math>, <mml:math id="jats-math-113"><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.277778em"/><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0.1480</mml:mn></mml:mrow></mml:math>, and <mml:math id="jats-math-114"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0.1026</mml:mn></mml:mrow></mml:math>. Nonetheless, these parameter values may be changed by regulatory agencies to restrict the tolerated IIV.</p><p>Finally, when IIV<sub>T</sub> &lt; IIV<sub>R</sub>, ABE draws once again different conclusions depending on IIV<sub>T</sub> and sample size. If IIV<sub>T</sub> = 1, ABE concludes to bioequivalence. Contrarily, if IIV<sub>T</sub> = 1.5, ABE does not conclude to bioequivalence for a small sample size. However, when the sample size is increased to 100, ABE can conclude to bioequivalence. PBE and TBE always conclude to bioequivalence regardless of sample size.</p></sec><sec id="psp412775-sec-0013"><title>Type 1 and type 2 errors</title><p>Table&#160;<xref rid="psp412775-tbl-0003" ref-type="table">3</xref> provides the type 1 and type 2 errors for all tested sample sizes. When the sample size is 10, the type 1 error exceeds 5% for ABE and TBE. It is 5.4%, 2.3%, and 15.6% for ABE, PBE, and TBE, respectively. We also note that the type 1 error with TBE is greater when the sample size is small (10 and 20 patients). For all other sample sizes, the type 1 error is below the acceptable 5% threshold and shows a satisfactory level of rejection of the null hypothesis. The type 1 error was also computed for cases where <mml:math id="jats-math-115"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8712;</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math> and was evaluated at 0% for all tested sample sizes (results not shown).</p><table-wrap position="float" id="psp412775-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Type 1 and Type 2 errors</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Sample size</th><th valign="top" rowspan="1" colspan="1">ABE</th><th valign="top" rowspan="1" colspan="1">PBE</th><th valign="top" rowspan="1" colspan="1">TBE</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Type 1 error<xref rid="psp412775-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">5.4</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="." rowspan="1" colspan="1">15.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">4.3</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">7.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">4.8</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">60</td><td align="char" char="." rowspan="1" colspan="1">5.4</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" rowspan="1">Type 2 error<xref rid="psp412775-note-0009" ref-type="table-fn">
<sup>b</sup>
</xref> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">15.2</td><td align="char" char="." rowspan="1" colspan="1">55.1</td><td align="char" char="." rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">23.1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">7.3</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">60</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.7</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot id="psp412775-ntgp-0004"><fn id="psp412775-note-0007"><p>Abbreviations: <italic toggle="yes">&#956;<sub>T</sub>
</italic> and <italic toggle="yes">&#956;<sub>R</sub>
</italic>, averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; <mml:math id="jats-math-116"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mspace width="0.15em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.15em"/><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>, variances of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively; ABE, average bioequivalence; PBE, population bioequivalence; TBE, trapezoid bioequivalence.</p></fn><fn id="psp412775-note-0008"><label>
<sup>a</sup>
</label><p>The type 1 error was computed from simulations with <mml:math id="jats-math-117"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.0498</mml:mn></mml:mrow></mml:math> and <mml:math id="jats-math-118"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math>.</p></fn><fn id="psp412775-note-0009"><label>
<sup>b</sup>
</label><p>The type 2 error was computed from simulations with <mml:math id="jats-math-119"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math> and <mml:math id="jats-math-120"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math>.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The type 2 error presented in Table&#160;<xref rid="psp412775-tbl-0003" ref-type="table">3</xref>&#160;shows that the power of TBE is greater than that of ABE and PBE for all sample sizes. Specifically, we note that the type 2 error of TBE is very low for all sample sizes analyzed. Notably, the type 2 error with TBE is 1.2% for a sample size of 10, whereas it is 15.2% with ABE and 55.1% with PBE. When the sample sizes are greater than 10, the type 2 error is null for ABE and TBE, whereas those for PBE are higher.</p><p>Figure&#160;<xref rid="psp412775-fig-0003" ref-type="fig">3</xref> provides the power curves of ABE, PBE, and TBE, explicitly the probability of concluding bioequivalence for different values of <mml:math id="jats-math-121"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math> and samples. Among all simulations and sample sizes, TBE&#8217;s power was higher or similar to ABE&#8217;s and PBE&#8217;s power. Specifically, the minimal sample sizes that allow a power larger than 80% are 20, 40, and 10, respectively, for ABE, PBE, and TBE. We note that the power for larger sample sizes decreased as <mml:math id="jats-math-122"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math> approaches its maximum threshold. In other words, larger sample sizes allow a more precise and accurate assessment of true BIE.</p><fig position="float" fig-type="FIGURE" id="psp412775-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Power curve for <mml:math id="jats-math-123"><mml:mrow><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mfenced close="}" open="{" separators=""><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.01</mml:mn><mml:mo>,</mml:mo><mml:mn>0.04</mml:mn><mml:mo>,</mml:mo><mml:mn>0.0498</mml:mn><mml:mo>,</mml:mo><mml:mn>0.09</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math> applied to average bioequivalence (ABE), population bioequivalence (PBE), and trapezoid bioequivalence (TBE). The power of ABE, PBE, and TBE were evaluated through the simulations of 1000 trials with a crossover and nonreplicated design. Each simulation was applied to sample sizes of 10, 20, 40, 60, 80, and 100. <italic toggle="yes">&#956;<sub>T</sub>
</italic> and <italic toggle="yes">&#956;<sub>R</sub>
</italic> are the averages of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-11-482-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="psp412775-sec-0014"><title>DISCUSSION</title><p>Several bioequivalence methods have been proposed to solve the issues of ABE and PBE.<xref rid="psp412775-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp412775-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="psp412775-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> As an alternative bioequivalence method, we propose the aggregate bioequivalence criterion TBE that encompasses ABE and PBE. TBE can balance the similarity in both formulations&#8217; average (<italic toggle="yes">&#956;</italic>) and variance (<italic toggle="yes">&#963;</italic>
<sup>2</sup>) of bioavailability at the same time. Moreover, this balance can be adapted to specific pharmacological characteristics through weights applied in TBE. For example, the weight of the difference of variance may be chosen larger for drugs with large IIV to ensure the best substitutability for a patient.</p><p>Table&#160;<xref rid="psp412775-tbl-0004" ref-type="table">4</xref>&#160;summarizes TBE&#8217;s appealing properties as observed from the scenario&#8208;based simulations and the MPH case studies. For the former, each scenario was chosen to demonstrate TBE&#8217;s properties in various clinical settings and to compare them to ABE and PBE. We analyzed small and large <mml:math id="jats-math-124"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>, large mean difference between the test and reference formulation, substitutable and nonsubstitutable formulations according to a therapeutically defined tolerance of variability. These scenarios allowed us to identify inadequacies of ABE and PBE and to confirm TBE&#8217;s strengths. Namely, we first showed that an increase in <mml:math id="jats-math-125"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> did not change TBE&#8217;s acceptable limits of bioequivalence. Indeed, TBE&#8217;s probability of passing bioequivalence was identical whether <mml:math id="jats-math-126"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math> or <mml:math id="jats-math-127"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1225</mml:mn></mml:mrow></mml:math>. This was not the case for PBE, where comparable levels of <mml:math id="jats-math-128"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math> and <mml:math id="jats-math-129"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math> resulted in opposite conclusions of bioequivalence depending on <mml:math id="jats-math-130"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>. In addition, we showed that TBE is not overly permissive compared with ABE when <mml:math id="jats-math-131"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, contrary to PBE. On the other hand, when <mml:math id="jats-math-132"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>, we define TBE to differ from ABE by imposing a clinically defined threshold on <mml:math id="jats-math-133"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> and proportionally reducing the threshold on <mml:math id="jats-math-134"><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math>. This property was only observed when the sample size was high enough for ABE to lead to bioequivalence (results not shown with scenario&#8208;based simulations).</p><table-wrap position="float" id="psp412775-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Desirable properties of ABE, PBE, and TBE</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Properties</th><th align="left" valign="top" rowspan="1" colspan="1">ABE</th><th align="left" valign="top" rowspan="1" colspan="1">PBE</th><th align="left" valign="top" rowspan="1" colspan="1">TBE</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sensitive to <italic toggle="yes">&#956;</italic> and <italic toggle="yes">&#963;</italic>
<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Interpreted on the normal scale</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Stable results with different <italic toggle="yes">n</italic>
</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">&#8730;</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Stable results with different <mml:math id="jats-math-135"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math>
</td><td align="left" rowspan="1" colspan="1">X<xref rid="psp412775-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">X<xref rid="psp412775-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Stable results when <mml:math id="jats-math-136"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math>
</td><td align="left" rowspan="1" colspan="1">&#8730;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">
<bold>&#8730;</bold>
</td></tr></tbody></table><table-wrap-foot id="psp412775-ntgp-0005"><title>
Note:
</title><fn id="psp412775-note-1010"><label>&#8730;</label><p>Signifies that the property applies to the bioequivalence method and X signifies that the property does not apply to the bioequivalence method</p></fn><fn id="psp412775-note-0010"><p>Abbreviations: ABE, average bioequivalence; PBE, population bioequivalence; TBE, trapezoid bioequivalence; &#956;, average of the bioavailability metrics on the logarithmic scale; &#963;, variance of the bioavailability metrics on the logarithmic scale; &#963;<sup>2</sup>
<sub>T</sub> and &#963;<sup>2</sup>
<sub>R</sub>, the variances of the bioavailability metrics on the logarithmic scale for the test and reference formulations, respectively.</p></fn><fn id="psp412775-note-0011"><label>
<sup>a</sup>
</label><p>If <mml:math id="jats-math-137"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is large, bioequivalence is less permissive.</p></fn><fn id="psp412775-note-0012"><label>
<sup>b</sup>
</label><p>If <mml:math id="jats-math-138"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math> is large, bioequivalence is more permissive.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>We explored additional conditions of variability and sample size through a pop&#8208;PK model of extended release MPH.<xref rid="psp412775-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> By varying the IIV on absorption parameters and testing a larger sample size, we simulated IIV<sub>T</sub> = IIV<sub>R</sub>, IIV<sub>T</sub> &gt; IIV<sub>R</sub>, and IIV<sub>T</sub> &lt; IIV<sub>R</sub> when the sample size is 40 or 100&#160;subjects. All results concurred with the scenario&#8208;based method. We observed again PBE&#8217;s increased permissiveness as we reduce IIV<sub>T</sub>. Furthermore, as the sample size increased, we observed an agreement between the results from ABE and TBE. These results complemented the scenario&#8208;based simulations and confirmed that TBE&#8217;s permissiveness was only apparent and dependent on the study sample size.</p><p>An interesting feature of TBE was demonstrated in the type 2 error computations. Indeed, higher or similar power may be achieved with TBE across all sample sizes compared with ABE and PBE. Thus, although ABE supposes that there is no difference in variance between both drugs, TBE imposes an explicit restriction to <mml:math id="jats-math-139"><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#8208;</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math> without additional cost to the type 2 errors. We note that the use of 90% CI reduces the fixed maximum threshold of <mml:math id="jats-math-140"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math>. Namely, we find that only simulations where the sample <mml:math id="jats-math-141"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>&lt;</mml:mo><mml:mn>0.0365</mml:mn></mml:mrow></mml:math>, <mml:math id="jats-math-142"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>&lt;</mml:mo><mml:mn>0.0055</mml:mn><mml:mspace width="0.277778em"/><mml:mtext>or</mml:mtext><mml:mspace width="0.277778em"/><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>&lt;</mml:mo><mml:mn>0.025</mml:mn></mml:mrow></mml:math> were declared bioequivalent with ABE, PBE, and TBE, respectively. Because the <mml:math id="jats-math-143"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#8208;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math> limit of TBE is further removed from its theoretical value than in the case of ABE, future work should improve TBE&#8217;s computation of 90% CI and replace the current use of the bootstrap.</p><p>In addition, the type 1 error is dependent on sample size for TBE, which is contrary to statistical definitions of the type 1 error. We hypothesize that it is due to the nonparametric bootstrap in TBE&#8217;s CI, which transfers its dependance on sample size to the type 1 error.<xref rid="psp412775-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="psp412775-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="psp412775-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The authors chose a nonparametric bootstrap to compute the TBE&#8217;s CI as it does not rely on any assumptions and it is the most accessible.</p><p>We acknowledge that the application of TBE is limited to cases where the variability has a significant impact on treatment. The example we chose in our work is MPH, whose dose individualization is challenging because of its large IIV. As well, it is known that MPH&#8217;s therapeutic effect closely follows its pharmacokinetics. Thus, it is our hypothesis that controlling for variability between test and reference formulations will reduce the titration period by increasing drug substitutability.</p><p>In conclusion, the clinically inspired simulations showed TBE&#8217;s superiority in a reasonable context and its potential usefulness in practice. Indeed, TBE is mathematically accessible, and its statistical analysis is not more complex than PBE. As well, a standard 2 &#215; 2 crossover design is sufficient to estimate TBE. Furthermore, TBE&#8217;s parameters (<mml:math id="jats-math-144"><mml:msup><mml:mi>&#952;</mml:mi><mml:mi mathvariant="normal">TBE</mml:mi></mml:msup></mml:math> and <mml:math id="jats-math-145"><mml:mrow><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#945;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math>) permit a highly flexible approach. Although these parameters were specifically fixed to values justified for MPH in this work, they can be modified to reflect any drug's pharmacological and pharmacodynamic characteristics. For example, stricter limits can be established by regulatory agencies for narrow therapeutic drugs that require close titration (insulin, blood thinners, anticonvulsants, etc.). Further work on TBE should involve work on the calculation of the CI, and estimation of optimal sample size must be applied to complete work on TBE.</p></sec><sec sec-type="COI-statement" id="psp412775-sec-0015"><title>CONFLICT OF INTEREST</title><p>The authors declared no competing interests for this work.</p></sec><sec id="psp412775-sec-0016"><title>AUTHOR CONTRIBUTIONS</title><p>S.S., J.L., and F.N. wrote the manuscript. S.S., J.L., and F.N. designed the research. S.S. performed the research and analyzed the data.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp412775-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Figure S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-482-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412775-sup-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-482-s004.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412775-sup-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S2</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-482-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412775-sup-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-482-s005.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412775-sup-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material S2</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-482-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="psp412775-bibl-0001"><title>REFERENCES</title><ref id="psp412775-bib-0001"><label>1</label><mixed-citation publication-type="book" id="psp412775-cit-0001"><collab collab-type="authors">US Food and Drug Administration</collab>
. <source>Abbreviated New Drug Application (ANDA)</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda" ext-link-type="uri">https://www.fda.gov/drugs/types&#8208;applications/abbreviated&#8208;new&#8208;drug&#8208;application&#8208;anda</ext-link>. Published <year>2019</year>. Accessed May 21, 2021.</mixed-citation></ref><ref id="psp412775-bib-0002"><label>2</label><mixed-citation publication-type="book" id="psp412775-cit-0002"><collab collab-type="authors">US Food and Drug Administration</collab>
. <source>Guidance for industry. Statistical approaches to establishing bioequivalence</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence" ext-link-type="uri">https://www.fda.gov/regulatory&#8208;information/search&#8208;fda&#8208;guidance&#8208;documents/statistical&#8208;approaches&#8208;establishing&#8208;bioequivalence</ext-link>. Published <year>2001</year>. Accessed October 22, 2020.</mixed-citation></ref><ref id="psp412775-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp412775-cit-0003"><string-name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></string-name>. <article-title>Bioequivalence revisited</article-title>. <source>Stat Med</source>. <year>1992</year>;<volume>11</volume>(<issue>13</issue>):<fpage>1777</fpage>&#8208;<lpage>1788</lpage>.<pub-id pub-id-type="pmid">1485060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4780111311</pub-id></mixed-citation></ref><ref id="psp412775-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp412775-cit-0004"><string-name name-style="western"><surname>Hauck</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>S</given-names></string-name>. <article-title>Measuring switchability and prescribability: when is average bioequivalence sufficient?</article-title><source>J Pharmacokinet Biopharm</source>. <year>1994</year>;<volume>22</volume>(<issue>6</issue>):<fpage>551</fpage>&#8208;<lpage>564</lpage>.<pub-id pub-id-type="pmid">7473081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02353794</pub-id></mixed-citation></ref><ref id="psp412775-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="psp412775-cit-0005"><string-name name-style="western"><surname>Steinijans</surname><given-names>VW</given-names></string-name>. <article-title>Some conceptual issues in the evaluation of average, population, and individual bioequivalence</article-title>. <source>Therapeutic Innovat Regulat Sci</source>. <year>2001</year>;<volume>35</volume>(<issue>3</issue>):<fpage>893</fpage>&#8208;<lpage>899</lpage>.</mixed-citation></ref><ref id="psp412775-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp412775-cit-0006"><string-name name-style="western"><surname>Hyslop</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hsuan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Holder</surname><given-names>DJ</given-names></string-name>. <article-title>A small sample con&#255;dence interval approach to assess individual bioequivalence</article-title>. <source>Stat Med</source><year>2000</year>;<volume>13</volume>:<fpage>2885</fpage>&#8208;<lpage>2897</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0258(20001030)19:20&lt;2885::aid-sim553&gt;3.0.co;2-h</pub-id><pub-id pub-id-type="pmid">11033583</pub-id></mixed-citation></ref><ref id="psp412775-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp412775-cit-0007"><string-name name-style="western"><surname>Schall</surname><given-names>R</given-names></string-name>. <article-title>Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar</article-title>. <source>Biometrics</source>. <year>1995</year>;<volume>51</volume>(<issue>2</issue>):<fpage>615</fpage>&#8208;<lpage>626</lpage>.<pub-id pub-id-type="pmid">7662849</pub-id></mixed-citation></ref><ref id="psp412775-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp412775-cit-0008"><string-name name-style="western"><surname>Endrenyi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>Y</given-names></string-name>. <article-title>Asymmetry of the mean&#8208;variability trade&#8208;off raises questions about the model in investigations of individual bioequivalence</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>1998</year>;<volume>36</volume>(<issue>8</issue>):<fpage>450</fpage>&#8208;<lpage>457</lpage>.<pub-id pub-id-type="pmid">9726700</pub-id></mixed-citation></ref><ref id="psp412775-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp412775-cit-0009"><string-name name-style="western"><surname>Nakai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fujita</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tomita</surname><given-names>M</given-names></string-name>. <article-title>Comparison of average and population bioequivalence approach</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2002</year>;<volume>40</volume>(<issue>9</issue>):<fpage>431</fpage>&#8208;<lpage>438</lpage>.<pub-id pub-id-type="pmid">12358161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5414/cpp40431</pub-id></mixed-citation></ref><ref id="psp412775-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="psp412775-cit-0010"><string-name name-style="western"><surname>Barrett</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Batra</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>A</given-names></string-name>, et al. <article-title>PhRMA perspective on population and individual bioequivalence</article-title>. <source>J Clin Pharmacol</source>. <year>2000</year>;<volume>40</volume>(<issue>6</issue>):<fpage>561</fpage>&#8208;<lpage>570</lpage>.<pub-id pub-id-type="pmid">10868305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.2000.tb05980.x</pub-id></mixed-citation></ref><ref id="psp412775-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="psp412775-cit-0011"><string-name name-style="western"><surname>Zariffa</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>SD</given-names></string-name>. <article-title>Population and individual bioequivalence: lessons from real data and simulation studies</article-title>. <source>J Clin Pharmacol</source>. <year>2001</year>;<volume>41</volume>(<issue>8</issue>):<fpage>811</fpage>&#8208;<lpage>822</lpage>.<pub-id pub-id-type="pmid">11504268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912700122010708</pub-id></mixed-citation></ref><ref id="psp412775-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp412775-cit-0012"><string-name name-style="western"><surname>Dragalin</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Fedorov</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>B</given-names></string-name>. <article-title>Kullback&#8208;Leibler divergence for evaluating bioequivalence</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>(<issue>6</issue>):<fpage>913</fpage>&#8208;<lpage>930</lpage>.<pub-id pub-id-type="pmid">12627409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.1451</pub-id></mixed-citation></ref><ref id="psp412775-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp412775-cit-0013"><string-name name-style="western"><surname>Hauck</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Hyslop</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Patnaik</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schuirmann</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>R</given-names></string-name>. <article-title>Mean difference vs. variability reduction: trade&#8208;offs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>1996</year>;<volume>34</volume>(<issue>12</issue>):<fpage>535</fpage>&#8208;<lpage>541</lpage>.<pub-id pub-id-type="pmid">8996848</pub-id></mixed-citation></ref><ref id="psp412775-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp412775-cit-0014"><string-name name-style="western"><surname>Karalis</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Symillides</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Macheras</surname><given-names>P</given-names></string-name>. <article-title>Novel methods to assess bioequivalence</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2011</year>;<volume>7</volume>(<issue>1</issue>):<fpage>79</fpage>&#8208;<lpage>88</lpage>.<pub-id pub-id-type="pmid">21118059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2011.539202</pub-id></mixed-citation></ref><ref id="psp412775-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp412775-cit-0015"><string-name name-style="western"><surname>Pereira</surname><given-names>LM</given-names></string-name>. <article-title>Bioequivalence testing by statistical shape analysis</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2007</year>;<volume>34</volume>(<issue>4</issue>):<fpage>451</fpage>&#8208;<lpage>484</lpage>.<pub-id pub-id-type="pmid">17554610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10928-007-9055-3</pub-id></mixed-citation></ref><ref id="psp412775-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp412775-cit-0016"><string-name name-style="western"><surname>Polli</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>AM</given-names></string-name>. <article-title>Novel direct curve comparison metrics for bioequivalence</article-title>. <source>Pharm Res</source>. <year>2001</year>;<volume>18</volume>(<issue>6</issue>):<fpage>734</fpage>&#8208;<lpage>741</lpage>.<pub-id pub-id-type="pmid">11474775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011067908500</pub-id></mixed-citation></ref><ref id="psp412775-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp412775-cit-0017"><string-name name-style="western"><surname>Marston</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Polli</surname><given-names>JE</given-names></string-name>. <article-title>Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence</article-title>. <source>Pharm Res</source>. <year>1997</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1363</fpage>&#8208;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">9358548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1012160419520</pub-id></mixed-citation></ref><ref id="psp412775-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp412775-cit-0018"><string-name name-style="western"><surname>Midha</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Rawson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Hubbard</surname><given-names>JW</given-names></string-name>. <article-title>Individual and average bioequivalence of highly variable drugs and drug products</article-title>. <source>J Pharm Sci</source>. <year>1997</year>;<volume>86</volume>(<issue>11</issue>):<fpage>1193</fpage>&#8208;<lpage>1197</lpage>.<pub-id pub-id-type="pmid">9383724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/js960516+</pub-id></mixed-citation></ref><ref id="psp412775-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp412775-cit-0019"><string-name name-style="western"><surname>Soufsaf</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Robaey</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bonnefois</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nekka</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>. <article-title>A quantitative comparison approach for methylphenidate drug regimens in attention&#8208;deficit/hyperactivity disorder treatment</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2019</year>;<volume>29</volume>(<issue>3</issue>):<fpage>220</fpage>&#8208;<lpage>234</lpage>.<pub-id pub-id-type="pmid">30714820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/cap.2018.0093</pub-id></mixed-citation></ref><ref id="psp412775-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="psp412775-cit-0020"><string-name name-style="western"><surname>Ermer</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Adeyi</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Pucci</surname><given-names>ML</given-names></string-name>. <article-title>Pharmacokinetic variability of long&#8208;acting stimulants in the treatment of children and adults with attention&#8208;deficit hyperactivity disorder</article-title>. <source>CNS Drugs</source>. <year>2010</year>;<volume>24</volume>(<issue>12</issue>):<fpage>1009</fpage>&#8208;<lpage>1025</lpage>.<pub-id pub-id-type="pmid">21090837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11539410-000000000-00000</pub-id></mixed-citation></ref><ref id="psp412775-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="psp412775-cit-0021"><string-name name-style="western"><surname>Yue</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Ozdin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Selber&#8208;Hnatiw</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ducharme</surname><given-names>MP</given-names></string-name>. <article-title>Opportunities and challenges related to the implementation of model &#8211; based bioequivalence criteria</article-title>. <source>Clin Pharm</source>. <year>2019</year>;<volume>105</volume>(<issue>2</issue>):<fpage>13</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1270</pub-id><pub-id pub-id-type="pmid">30375647</pub-id></mixed-citation></ref><ref id="psp412775-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="psp412775-cit-0022"><string-name name-style="western"><surname>Dubois</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gsteiger</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pigeolet</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></string-name>. <article-title>Bioequivalence Tests Based on Individual Estimates Using Non&#8208;compartmental or Model&#8208;Based Analyses: Evaluation of Estimates of Sample Means and Type I Error for Different Designs</article-title>; 13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-009-9980-5</pub-id><pub-id pub-id-type="pmcid">PMC2881952</pub-id><pub-id pub-id-type="pmid">19876723</pub-id></mixed-citation></ref><ref id="psp412775-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp412775-cit-0023"><string-name name-style="western"><surname>Mould</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Upton</surname><given-names>RN</given-names></string-name>. <article-title>Basic concepts in population modelling, simulation, and model&#8208;based drug development&#8208;part 2: introduction to pharmacokinetic modelling methods</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2013</year>;<volume>17</volume>(<issue>2</issue>):<fpage>e38</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.14</pub-id><pub-id pub-id-type="pmcid">PMC3636497</pub-id><pub-id pub-id-type="pmid">23887688</pub-id></mixed-citation></ref><ref id="psp412775-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp412775-cit-0024"><string-name name-style="western"><surname>Wellek</surname><given-names>S</given-names></string-name>. <article-title>On a reasonable disaggregate criterion of population bioequivalence admitting of resampling&#8208;free testing procedures</article-title>. <source>Stat Med</source>. <year>2000</year>;<volume>19</volume>(<issue>20</issue>):<fpage>2755</fpage>&#8208;<lpage>2767</lpage>.<pub-id pub-id-type="pmid">11033573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0258(20001030)19:20&lt;2755::aid-sim543&gt;3.0.co;2-o</pub-id></mixed-citation></ref><ref id="psp412775-bib-0025"><label>25</label><mixed-citation publication-type="book" id="psp412775-cit-0025"><string-name name-style="western"><surname>Chernick</surname><given-names>MR</given-names></string-name>. <source>Bootstrap Methods: A Guide for Practitioners and Researchers</source>. <edition>2</edition>nd ed. <publisher-name>Wiley&#8208;Interscience</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="psp412775-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp412775-cit-0026"><string-name name-style="western"><surname>Hesterberg</surname><given-names>TC</given-names></string-name>. <article-title>What teachers should know about the bootstrap: resampling in the undergraduate statistics curriculum</article-title>. <source>Am Stat</source>. <year>2015</year>;<volume>69</volume>(<issue>4</issue>):<fpage>371</fpage>&#8208;<lpage>386</lpage>.<pub-id pub-id-type="pmid">27019512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00031305.2015.1089789</pub-id><pub-id pub-id-type="pmcid">PMC4784504</pub-id></mixed-citation></ref><ref id="psp412775-bib-0027"><label>27</label><mixed-citation publication-type="book" id="psp412775-cit-0027"><string-name name-style="western"><surname>Bradley</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tibshirani</surname><given-names>RJ</given-names></string-name>. <source>An Introduction to the Bootstrap</source>. <publisher-name>Chapman and Hall</publisher-name>; <year>1993</year>. Monographs on Statistics and Applied Probability; vol 57.</mixed-citation></ref></ref-list></back></article></pmc-articleset>